Abstract
The posttranslational modification of proteins by a single O-linked N-acetylglucosamine (O-GlcNAc) is an intracellular biochemical reaction which is ubiquitous in eukaryotic cells. Two enzymes regulate the process: O-linked Nacetylglucosaminyltransferase (OGT), which attaches O-GlcNAc to serine/threonine residues of proteins, and a a-Nacetylglucosaminidase (O-GlcNAcase), that removes the O-GlcNAc group. The serine or threonine targeted by OGlcNAc can occur at sites modified by other enzymes such as protein kinases. There have been many indications that OGlcNAc modifications are actively involved in the regulation of the immune system and recent results have begun to shed light on possible mechanisms. This review summarizes recent advances in the field of O-GlcNAc modification, with a special attention to its role in the activation of lymphocytes.
Keywords: O-linked N-acetylglucosamine, O-GlcNAc, OGT, T-cell activation, B-cell activation
Current Signal Transduction Therapy
Title: Immune Regulation by the Posttranslational Modification O-GlcNAc
Volume: 5 Issue: 1
Author(s): Alexander Pappa and Danilo Guerini
Affiliation:
Keywords: O-linked N-acetylglucosamine, O-GlcNAc, OGT, T-cell activation, B-cell activation
Abstract: The posttranslational modification of proteins by a single O-linked N-acetylglucosamine (O-GlcNAc) is an intracellular biochemical reaction which is ubiquitous in eukaryotic cells. Two enzymes regulate the process: O-linked Nacetylglucosaminyltransferase (OGT), which attaches O-GlcNAc to serine/threonine residues of proteins, and a a-Nacetylglucosaminidase (O-GlcNAcase), that removes the O-GlcNAc group. The serine or threonine targeted by OGlcNAc can occur at sites modified by other enzymes such as protein kinases. There have been many indications that OGlcNAc modifications are actively involved in the regulation of the immune system and recent results have begun to shed light on possible mechanisms. This review summarizes recent advances in the field of O-GlcNAc modification, with a special attention to its role in the activation of lymphocytes.
Export Options
About this article
Cite this article as:
Pappa Alexander and Guerini Danilo, Immune Regulation by the Posttranslational Modification O-GlcNAc, Current Signal Transduction Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/157436210790226500
DOI https://dx.doi.org/10.2174/157436210790226500 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?
Current Neurovascular Research Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells
Current Drug Metabolism Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry